EA201170484A1 - Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950 - Google Patents

Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950

Info

Publication number
EA201170484A1
EA201170484A1 EA201170484A EA201170484A EA201170484A1 EA 201170484 A1 EA201170484 A1 EA 201170484A1 EA 201170484 A EA201170484 A EA 201170484A EA 201170484 A EA201170484 A EA 201170484A EA 201170484 A1 EA201170484 A1 EA 201170484A1
Authority
EA
Eurasian Patent Office
Prior art keywords
ribavirin
interferon
including peg
therapeutic mode
hepatitis treatment
Prior art date
Application number
EA201170484A
Other languages
English (en)
Russian (ru)
Inventor
Роберт С. Кауффман
Сирил Жан Камий Тите
Рамон Поло
Рудольф Петер Герхард Ван Хесвейк
Мария Глория Бемон
Гастон Рафаэл Пиккио
Original Assignee
Вертекс Фармасьютикалз Инкорпорейтед
Янссен Фармацевтика Нв
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Вертекс Фармасьютикалз Инкорпорейтед, Янссен Фармацевтика Нв filed Critical Вертекс Фармасьютикалз Инкорпорейтед
Publication of EA201170484A1 publication Critical patent/EA201170484A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/7056—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing five-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
EA201170484A 2008-09-24 2009-09-24 Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950 EA201170484A1 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US9984908P 2008-09-24 2008-09-24
US10965508P 2008-10-30 2008-10-30
US24304109P 2009-09-16 2009-09-16
PCT/US2009/058218 WO2010036799A1 (en) 2008-09-24 2009-09-24 Therapeutic regimen comprising peg- interferon, ribavirin and vx-950 for the treatment of hepatitis "

Publications (1)

Publication Number Publication Date
EA201170484A1 true EA201170484A1 (ru) 2012-03-30

Family

ID=41396114

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201170484A EA201170484A1 (ru) 2008-09-24 2009-09-24 Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950

Country Status (11)

Country Link
US (2) US20110236351A1 (enExample)
EP (1) EP2328656A1 (enExample)
JP (1) JP2012503669A (enExample)
KR (1) KR20110074870A (enExample)
CN (1) CN102316935A (enExample)
AU (1) AU2009296653A1 (enExample)
CA (1) CA2738477A1 (enExample)
EA (1) EA201170484A1 (enExample)
IL (1) IL211810A0 (enExample)
MX (1) MX2011003121A (enExample)
WO (1) WO2010036799A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8399615B2 (en) 2005-08-19 2013-03-19 Vertex Pharmaceuticals Incorporated Processes and intermediates
EA201170441A1 (ru) * 2008-10-15 2012-05-30 Интермьюн, Инк. Терапевтические противовирусные пептиды
EP2396028A2 (en) * 2009-02-12 2011-12-21 Vertex Pharmceuticals Incorporated Hcv combination therapies comprising pegylated interferon, ribavirin and telaprevir
US20110082182A1 (en) * 2009-10-01 2011-04-07 Intermune, Inc. Therapeutic antiviral peptides
PT107894A (pt) 2011-10-21 2014-10-31 Abbvie Inc Métodos para o tratamento de hcv compreendendo pelo menos dois agentes antivirais de actuação directa, ribavirina, mas não interferão.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
GB2515942A (en) 2011-10-21 2015-01-07 Abbvie Inc Combination treatment (e.g. with ABT-072 or ABT-333) of DAAs for use in treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
US11192914B2 (en) 2016-04-28 2021-12-07 Emory University Alkyne containing nucleotide and nucleoside therapeutic compositions and uses related thereto

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA200700030B (en) * 2004-06-08 2009-06-24 Vertex Pharma Pharmaceutical compositions
MY141025A (en) * 2004-10-29 2010-02-25 Vertex Pharma Dose forms
CA2650616A1 (en) * 2006-04-26 2007-11-08 Vertex Pharmaceuticals Incorporated Hepatitis c virus infection biomarkers
MX2009012598A (es) * 2007-05-21 2009-12-07 Vertex Pharma Formas de dosis que comprenden vx-950 y su regimen de dosificacion.

Also Published As

Publication number Publication date
CA2738477A1 (en) 2010-04-01
MX2011003121A (es) 2011-04-21
EP2328656A1 (en) 2011-06-08
WO2010036799A1 (en) 2010-04-01
JP2012503669A (ja) 2012-02-09
US20130101554A1 (en) 2013-04-25
AU2009296653A1 (en) 2010-04-01
KR20110074870A (ko) 2011-07-04
US8871812B2 (en) 2014-10-28
IL211810A0 (en) 2011-06-30
CN102316935A (zh) 2012-01-11
US20110236351A1 (en) 2011-09-29

Similar Documents

Publication Publication Date Title
EA201170484A1 (ru) Терапевтический режим лечения гепатита, включающий пэг-интерферон, рибавирин и vx-950
EA200900298A1 (ru) Ингибиторы вируса гепатита с
EA201201235A1 (ru) Комбинации фармацевтических агентов в качестве ингибиторов репликации hcv
EA201391519A1 (ru) 2'-замещенные нуклеозидные производные и способы их применения для лечения вирусных заболеваний
EA201170915A1 (ru) Фосфорамидатные производные гуанозиновых нуклеозидов для лечения вирусных инфекций
EA201171208A1 (ru) Ингибиторы вируса гепатита с
EA201101082A1 (ru) Ингибиторы вируса гепатита с
CY1114356T1 (el) Αναστολεις του ιου της ηπατιτιδας c
MA32634B1 (fr) Polytherapie destinee a traiter une infection par le vhc
EA201290882A1 (ru) Конденсированные трициклические силильные соединения и способы их применения для лечения вирусных заболеваний
EA201100390A1 (ru) Соединения для лечения гепатита с
EA201270656A1 (ru) Ингибиторы вируса гепатита с
EA201301078A1 (ru) Новые терапевтические подходы в лечении смт и связанных с ней расстройств
EA201490588A1 (ru) Способы лечения вируса гепатита с
EA201490254A1 (ru) Комбинированное лечение гепатита с
EA201490903A1 (ru) Композиции и способы лечения вирусного гепатита c
EA200970586A1 (ru) Антитела к цитомегаловирусу человека (hcmv)
EA200970375A1 (ru) Соединения и способы лечения вируса гепатита с
EA201270144A1 (ru) Комбинированная терапия при лечении диабета
TW200733953A (en) Materials and methods for treating viral infections
EA201300421A1 (ru) Комбинированная терапия для лечения инфекции hcv
EA201000277A1 (ru) Соединения для лечения гепатита с
EA201391685A1 (ru) Ингибиторы вируса гепатита с
EA201071043A1 (ru) Новые производные 1-бензил-3-гидроксиметилиндазола и их применение при лечении заболеваний, обусловленных экспрессией mcp-1 и cx3cr1
EA201071230A1 (ru) Лечение инфекций вирусом гепатита с телапревиром (vx-950) у пациентов, не отвечающих на лечение пегилированным интерфероном-альфа-2а/2в и рибавирином